NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc. announced that results from the Company’s RX-04 development program were featured today in 14 posters at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 17-20, 2011 in Chicago, IL. The RX-04 program is focused on the development of three completely novel classes of antibiotic compounds with efficacy against the most difficult to treat, clinically important, multi-drug resistant Gram-negative and Gram-positive pathogens, including NDM-1-producing Enterobacteriaceae, P. aeruginosa, A. baumannii and MRSA. In June 2011, Rib-X signed an exclusive worldwide research collaboration agreement and option for license with Sanofi for novel classes of antibiotics resulting from the RX-04 program.
